PD-L1 Up-Regulation in Prostate Cancer Cells by Porphyromonas gingivalis

被引:18
|
作者
Groeger, Sabine [1 ,2 ]
Wu, Fan [1 ]
Wagenlehner, Florian [3 ]
Dansranjav, Temuujin [3 ]
Ruf, Sabine [2 ]
Denter, Fabian [1 ]
Meyle, Joerg [1 ]
机构
[1] Justus Liebig Univ, Dept Periodontol, Giessen, Germany
[2] Justus Liebig Univ, Dept Orthodont, Giessen, Germany
[3] Justus Liebig Univ, Clin Urol, Giessen, Germany
来源
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY | 2022年 / 12卷
关键词
periodontitis; prostate cancer; Porphyromonas gingivalis; PD-L1; up-regulation; immune evasion; INFLAMMATION; INFECTION; IMMUNITY; PATHOGEN; NOD1;
D O I
10.3389/fcimb.2022.935806
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Chronic inflammation is known to contribute to various human cancers. Porphyromonas gingivalis (P. gingivalis), is a gram-negative oral keystone pathogen that may cause severe periodontitis and expresses several virulence factors to affect the host immune system. Periodontitis is a chronic infectious disease that while progression, may cause loss of attachment and destruction of the tooth supporting tissues. Prostate cancer is one of the most common malignancies in men. Increasing evidence links periodontitis with prostate cancer, however the mechanisms explaining this relationship remain unclear. The aim of this study was to investigate the expression and signaling pathway of programmed death ligand 1 (PD-L1) in a prostate cancer cell line after infection with P. gingivalis and stimulation with P. gingivalis components to reveal the mechanism of tumor-induced immune evasion associated with bacterial infection in the tumor environment. Prostate cancer cells were infected with different concentrations of viable P. gingivalis and treated with different concentrations of heat-killed P. gingivalis and P. gingivalis cell components, including the total membrane fraction, inner membrane fraction, outer membrane fraction, cytosolic fraction and peptidoglycan (PGN). Chemical inhibitors were used to block different important molecules of signaling pathways to assess the participating signal transduction mechanisms. PD-L1 expression was detected by Western blot after 24 h of infection. PD-L1 was demonstrated to be upregulated in prostate cancer cells after infection with viable and with heat-killed P. gingivalis membrane fractions. Also isolated PGN induced PD-L1 up-regulation. The upregulation was mediated by the NOD1/NOD2 signaling pathway. No upregulation could be detected after treatment of the cells with P. gingivalis lipopolysaccharide (LPS). These results indicate, that chronic inflammatory disease can contribute to tumor immune evasion by modifying the tumor microenvironment. Thus, chronic infection possibly plays an essential role in the immune response and may promote the development and progression of prostate cancer.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Cancer-associated oxidoreductase ERO1-α promotes immune escape through up-regulation of PD-L1 in human breast cancer
    Tanaka, Tsutomu
    Kutomi, Goro
    Kajiwara, Toshimitsu
    Kukita, Kazuharu
    Kochin, Vitaly
    Kanaseki, Takayuki
    Tsukahara, Tomohide
    Hirohashi, Yoshihiko
    Torigoe, Toshihiko
    Okamoto, Yoshiharu
    Hirata, Koichi
    Sato, Noriyuki
    Tamura, Yasuaki
    ONCOTARGET, 2017, 8 (15) : 24706 - 24718
  • [22] Current insight into the regulation of PD-L1 in cancer
    Zhuandi Liu
    Xibao Yu
    Ling Xu
    Yangqiu Li
    Chengwu Zeng
    Experimental Hematology & Oncology, 11
  • [23] Role of leptin in modulation of Porphyromonas gingivalis lipopolysaccharide-induced up-regulation of endothelin-1 in salivary gland acinar cells
    Slomiany, BL
    Slomiany, A
    IUBMB LIFE, 2005, 57 (08) : 591 - 595
  • [24] Prognostic significance of soluble PD-L1 in prostate cancer
    Zvirble, Margarita
    Survila, Zilvinas
    Bosas, Paulius
    Dobrovolskiene, Neringa
    Mlynska, Agata
    Zaleskis, Gintaras
    Jursenaite, Jurgita
    Characiejus, Dainius
    Pasukoniene, Vita
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [25] PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer
    Yang, Shijie
    Zhang, Qiuyang
    Liu, Sen
    Wang, Alun R.
    You, Zongbing
    AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY, 2016, 4 (01): : 1 - 8
  • [26] PD-1/PD-L1 pathway inhibitors in advanced prostate cancer
    Velho, Pedro Isaacsson
    Antonarakis, Emmanuel S.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (05) : 475 - 486
  • [27] The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer
    Xu, Yichi
    Song, Gendi
    Xie, Shangdan
    Jiang, Wenxiao
    Chen, Xin
    Chu, Man
    Hu, Xiaoli
    Wang, Zhi-Wei
    MOLECULAR THERAPY, 2021, 29 (06) : 1958 - 1969
  • [28] Intrahepatic PD-1/PD-L1 Up-regulation Closely Correlates with Inflammation and Virus Replication in Patients with Chronic HBV Infection
    Xie, Zhunyi
    Chen, Yongwen
    Zhao, Songtao
    Yang, Zhiqing
    Yao, Xiaohong
    Guo, Sheng
    Yang, Chengying
    Fei, Lei
    Zeng, Xingguang
    Ni, Bing
    Wu, Yuzhang
    IMMUNOLOGICAL INVESTIGATIONS, 2009, 38 (07) : 624 - 638
  • [29] Regulation of PD-L1 expression on cancer cells with ROS-modulating drugs
    Bailly, Christian
    LIFE SCIENCES, 2020, 246
  • [30] Mechanobiology of Lung Cancer Cells: Regulation of PD-L1 Expression by Matrix Stiffness
    Miyazawa, A.
    Ito, S.
    Asano, S.
    Tanaka, I.
    Sato, M.
    Kondo, M.
    Hasegawa, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S518 - S518